{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:27:56Z","timestamp":1786969676166,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    <jats:sup>68<\/jats:sup>\n                    Gallium NODAGA-JR11, a somatostatin receptor (SSTR) antagonist, exhibits superior sensitivity in detecting hepatic metastases of neuroendocrine tumors compared with the agonist tracer\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTANOC PET\/CT. In the presented case of rectal neuroendocrine tumor, both tracers identified the primary lesion and regional lymph node involvement; however, NODAGA-JR11 PET\/CT revealed multiple hepatic metastases not visualized on DOTANOC imaging, resulting in disease upstaging. The enhanced lesion detection is attributed to the antagonist\u2019s ability to bind a greater number of receptor sites and reduced hepatic background uptake. These findings highlight the potential impact of NODAGA-JR11 PET\/CT on clinical staging and therapeutic decision-making in metastatic neuroendocrine tumors.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006649","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:02:31Z","timestamp":1786968151000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["SSTR Antagonist PET\/CT Unveils Occult Hepatic Metastases in Rectal Neuroendocrine Tumor"],"prefix":"10.1097","author":[{"given":"Mehul","family":"Taggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim A.","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman K.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.117.199737","article-title":"Distribution, metabolism, and dosimetry of 68Ga-containing opsonic peptide 202 in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Nicolas","year":"2018","journal-title":"J Nucl Med"},{"key":"R2-20260817","first-page":"1651","article-title":"Somatostatin receptor antagonists for molecular imaging and therapy","volume":"59","author":"Fani","year":"2018","journal-title":"J Nucl Med"},{"key":"R3-20260817","first-page":"1495","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine neoplasms","volume":"48","author":"Treglia","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20260817","first-page":"1607","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy","volume":"41","author":"Wild","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2967\/jnumed.122.264890","article-title":"Head-to-head comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET\/CT in gastroenteropancreatic neuroendocrine tumors","volume":"64","author":"Lin","year":"2023","journal-title":"J Nucl Med"},{"key":"R6-20260817","first-page":"1083","article-title":"Comparative pharmacokinetics and imaging properties of somatostatin receptor PET ligands: 68Ga-DOTATATE versus 68Ga-NODAGA-JR11","volume":"46","author":"Zhu","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl 3","key":"R7-20260817","first-page":"1707","article-title":"Safety, biodistribution, and radiation dosimetry of the albumin-binding 68Ga-NODAGA-JR11 in patients with neuroendocrine tumors","volume":"58","author":"Nicolas","year":"2017","journal-title":"J Nucl Med"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00259-020-04832-9","article-title":"Biodistribution and radiation dosimetry of a novel somatostatin receptor antagonist 68Ga-DOTA-JR11 in patients with gastroenteropancreatic neuroendocrine tumors","volume":"47","author":"Krebs","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:02:32Z","timestamp":1786968152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006649"}},"subtitle":["Superiority Over 68Ga-DOTANOC and Clinical Upstaging"],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":8,"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006649","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"2026-04-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}